BLUE News and Press, bluebird bio Inc. From 09/06/21

MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...

CRISPR biotech companies have been showing promising clinical trial data, validating the technology as a disruptive force within the industry, pushing the sector's shares higher. NTLA's bold bet on its LNP delivery system paid off, expanding CRISPR applications beyond the Hematologic ...

CRISPR Therapeutics' clinical programs are progressing nicely, showing excellent safety and efficacy, validating the prospects of its novel technology as a disruptive force in the biotech industry. Directionally, we see CRSP focusing on next-generation CAR-T and regenerative therapies...

Shares of SPAC Blue Water Acquisition Corp. (NASDAQ:BLUE) are up more than 178% in premarket trading on the eve of a shareholder vote to combine with Clarus Therapeutics. As a combined entity, the company plans to accelerate commercialization of an oral testosterone replacement ther...

Volatility comes with the territory when you invest in biotech stocks. But sometimes the pullbacks with these stocks present fantastic buying opportunities for long-term investors. We asked three Motley Fool contributors which beaten-down biotech stocks they thought were great picks to ...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into bluebird bio, Inc. (NasdaqGS: BLUE). In May 2020, the Company announced its plans t...

BLUE is trading near its cash/cash equivalent per share, pointing that the ticker is oversold. The market reaction to the SUSAR case in eli-cel program relates to lost opportunities of leveraging the underlying technology, instead of the direct economic loss of commercializing Skysona...

bluebird continues to struggle with their gene therapy programs. The company announced that the FDA placed another clinical hold on one of their gene therapy programs. The company recently reported their Q2 earnings which revealed a big miss on EPS and revenue. In addition, the compan...

Gainers: Golden Nugget Online Gaming (NASDAQ:GNOG) +48%. Tarena International (NASDAQ:TEDU) +43%. SCWorx (NASDAQ:WORX) +32%. Select Interior Concepts (NASDAQ:SIC) +30%. Washington Prime Group (NYSE:WPG) +30%. The9 Limited (NASDAQ:NCTY) +27%. Sphere 3D (NASDAQ:ANY) +26%. Liminal BioSciences (N...

Bluebird Bio, Inc. (BLUE) Q2 2021 Earnings Conference Call August 09, 2021, 08:00 AM ET Company Participants Nick Leschly – Chief Executive Officer Elizabeth Pingpank – Direct Investor Relations Andrew Obenshain – President Severe Genetic Diseases Philip Gregory – ...